Selective OX1R antagonists target reward/metabolic imbalance in addiction-linked obesity, while agonists (e.g., orexin-A mimetics) could treat narcolepsy-associated IR by enhancing muscle uptake. This evidence concerns the gene HCRT and obesity disorder.